Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

Conference Call Scheduled for 10:00 a.m. ET Today

SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue. This event-driven interim analysis was designed to determine whether the study should continue to completion and took place in the time frame originally estimated. As is customary to preserve study blinding, the IDMC provided no information to the company other than the recommendation to continue the trial.

"The IDMC's recommendation to continue with the VITAL-1 trial represents an important step forward in the Phase 3 development of GVAX immunotherapy for prostate cancer and in our effort to make this product available as a new treatment option for men with prostate cancer," stated Robert Dow, MBChB, chief medical officer of Cell Genesys. "Moreover, we can currently estimate that we will reach the required number of events needed to conduct the final analysis in the second half of 2009."

VITAL-1 is a multi-center, randomized, controlled Phase 3 clinical trial designed to compare GVAX cancer immunotherapy to Taxotere(R) (docetaxel) chemotherapy plus prednisone in hormone refractory prostate cancer (HRPC) patients with metastatic disease who are asymptomatic with respect to cancer- related pain. The primary endpoint of the trial is an improvement in survival. VITAL-1 was initiated in July 2004 and completed recruitment of 626 patients in July 2007. Patients were enrolled at approximately 130 sites in North
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The clinical and ... be the difference between a product,s success or failure. ... and stratify KOL targets – and then to coordinate ... of strong relationships upon which successful KOL engagement rests. ... companies have identified internal inconsistencies in their KOL management ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
(Date:8/29/2014)... Mass. , Aug. 29, 2014  A ... prospective, multinational study on stent removability and preliminary ... has been published in the August issue of ... multinational study 1 is being conducted in ... of fully covered self-expanding metal stents (FCSEMS) after ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... Expensive drug development processes, rising competition and evolving ... commercialization strategies earlier and earlier into the new ... study, Pharmaceutical New Product Commercialization: Preparing for ... excerpt) , reveals that 61% of benchmarked ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... filed an Abbreviated New Drug Application (ANDA) with ... approval to market lisdexamfetamine dimesylate capsules.  Watson,s lisdexamfetamine ... LLC,s Vyvanse®. Vyvanse® is a prescription medicine for ...
Cached Medicine Technology:Early Stage Commercialization: Keys to Successful New Product Launch 2Watson Confirms Vyvanse® Patent Challenge 2
(Date:8/30/2014)... The establishment and creation of ... one of the main strategies of the Church ... impact around the world. , Architecturally stellar buildings ... executives and trainers deliver L. Ron Hubbard's spiritual ... statistics demonstrate that significant reduction in crime, major ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... 30, 2014 Hastings and Hastings, a ... located throughout Arizona is pleased to report having saved ... specific example among many cases where Hastings and Hastings ... to retain a greater portion of their settlement or ... providing a positive solution for Arizona car accident victims ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... August 30, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... ... sunscreen provides broad spectrum protection for skin from the sun,s harmful rays. , ... (PRWEB) June 30, 2010 ... is introducing a non-chemical natural sunscreen armed with unparalleled protection, barely-there feel, ...
... on recently-enacted health care reform legislation, the Patient Protection ... the American College of Physicians (ACP). An Internist,s ... by ACP,s Division of Governmental Affairs and Public Policy, ... health care reform legislation. "This 91-page document features ...
... Planet Symposium is on the innovative SMOS mission, which recently ... first observations due to be released in early July. ... in November to gather data on moisture in the surface ... oceans. SMOS will improve our understanding of the water cycle ...
... There ... given the large number of over-the-counter (OTC) pediatric product recalls as well as the dangerous ... ... filled with bumps, boos, strains and sprains. And with more children participating in rough ...
... ... platform for both Men and Women to ask their questions and give their answers. It seems ... offers a daily updated blog, with the ability to let users send their articles to be ... ...
... ... Channel® continue to beat expectations , , ... (PRWEB) June 30, 2010 -- Healing HealthCare Systems (HHS) based ... growth and consistent demand for its industry-leading product, The C.A.R.E. Channel , evidence-based relaxation ...
Cached Medicine News:Health News:As Summer Heats Up, Glacier Creme Debuts the Ultimate in Natural Sunscreen: 'Naked Protection' with Zinc Oxide 2Health News:Resource guide for internists released by ACP 2Health News:SMOS shines at symposium 2Health News:Topricin Junior: The Safe New Choice for Children's Pain Relief 2Health News:Topricin Junior: The Safe New Choice for Children's Pain Relief 3Health News:Get All Your Questions About Women and Relationships Solved Online At WomanAdvice.com 2Health News:Get All Your Questions About Women and Relationships Solved Online At WomanAdvice.com 3Health News:High Customer Retention and Continual Product Demand Drive Steady Growth for Innovative Healthcare Company 2
... These award-winning surgical loupes from SheerVision ... users - high resolution optics combined with ... "xx" Ultra-Light loupes weight as little as ... titanium frame, and are available in either ...
... SheerVision manufactures its signature line of ... Sport Frame. These next generation loupes ... ultra-lightweight design, and are multi-coated lens for ... the SV Sport frame offers a stylish, ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
Medicine Products: